Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
March 25 2024 - 2:00AM
Valneva Announces Filing of 2023 Universal Registration Document
and US Form 20-F
Saint-Herblain (France), March 25, 2024 –
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
company, announced today the filing, on March 22, 2024, of its 2023
Universal Registration Document (URD) with the French Financial
Markets Authority (AMF) under the filing number D.24-0157 and its
Form 20-F with the U.S. Securities and Exchange Commission
(SEC).
Valneva’s 2023 Universal Registration Document –
available in its entirety in French – includes the Company’s 2023
Annual Financial Report, the Company's Annual Management Report,
the Board of Directors’ Corporate Governance Report and the
Company’s Sustainability Report. The Sustainability Report is
available in both English and French.
These documents are available on Valneva’s
website (https://valneva.com/investors/financial-reports/) and will
also be available on the AMF (www.amf-france.org/) and SEC
(www.sec.gov/) websites, respectively. Hard copies of these
documents may be obtained from the Company, free of charge, upon
request at the following address: 6 rue Alain Bombard, 44800
Saint-Herblain, France.
About Valneva SE
We are a specialty vaccine company that
develops, manufactures, and commercializes prophylactic vaccines
for infectious diseases addressing unmet medical needs. We take a
highly specialized and targeted approach, applying our deep
expertise across multiple vaccine modalities, focused on providing
either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced
multiple vaccines from early R&D to approvals, and currently
market three proprietary travel vaccines, including the world’s
first and only chikungunya vaccine, as well as certain third-party
vaccines.
Revenues from our growing commercial business
help fuel the continued advancement of our vaccine pipeline. This
includes the only Lyme disease vaccine candidate in advanced
clinical development, which is partnered with Pfizer, as well as
vaccine candidates against the Zika virus and other global public
health threats.
Valneva Investor and Media ContactsLaetitia
Bachelot-FontaineVP, Global Communications and European Investor
RelationsM +33 (0)6 4516 7099communications@valneva.com |
Joshua Drumm, Ph.D.VP, Global Investor Relations M +001
917 815 4520joshua.drumm@valneva.com |
|
|
- 2024_03_25_VLA_URD_20F_Filing_PR_EN_Final
Valneva (TG:AYJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Valneva (TG:AYJ)
Historical Stock Chart
From Jul 2023 to Jul 2024